Sex steroid signaling: Implications for lung diseases

Venkatachalem Sathish, Yvette N. Martin, Y.s. Prakash

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

There is increasing recognition that sex hormones (estrogen, progesterone, and testosterone) have biological and pathophysiological actions in peripheral, non-reproductive organs, including the lung. Clinically, sex differences in the incidence, morbidity and mortality of lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, lung cancer and pulmonary hypertension have been noted, although intrinsic sex differences vs. the roles of sex steroids are still not well-understood. Accordingly, it becomes important to ask the following questions: 1) Which sex steroids are involved? 2) How do they affect different components of the lung under normal circumstances? 3) How does sex steroid signaling change in or contribute to lung disease, and in this regard, are sex steroids detrimental or beneficial? As our understanding of sex steroid signaling in the lung improves, it is important to consider whether such information can be used to develop new therapeutic strategies to target lung diseases, perhaps in both sexes or in a sex-specific manner. In this review, we focus on the basics of sex steroid signaling, and the current state of knowledge regarding how they influence structure and function of specific lung components across the life span and in the context of some important lung diseases. We then summarize the potential for sex steroids as useful biomarkers and therapeutic targets in these lung diseases as a basis for future translational research in the area of gender and individualized medicine.

Original languageEnglish (US)
Pages (from-to)94-108
Number of pages15
JournalPharmacology and Therapeutics
Volume150
DOIs
StatePublished - Jun 1 2015

Fingerprint

Lung Diseases
Steroids
Lung
Sex Characteristics
Precision Medicine
Translational Medical Research
Pulmonary Fibrosis
Gonadal Steroid Hormones
Pulmonary Hypertension
Chronic Obstructive Pulmonary Disease
Progesterone
Testosterone
Lung Neoplasms
Estrogens
Asthma
Biomarkers
Morbidity
Mortality
Incidence
Therapeutics

Keywords

  • Airway
  • Alveoli
  • Asthma
  • COPD
  • Estrogen
  • Hormone
  • Progesterone
  • Pulmonary fibrosis
  • Testosterone

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Sex steroid signaling : Implications for lung diseases. / Sathish, Venkatachalem; Martin, Yvette N.; Prakash, Y.s.

In: Pharmacology and Therapeutics, Vol. 150, 01.06.2015, p. 94-108.

Research output: Contribution to journalArticle

Sathish, Venkatachalem ; Martin, Yvette N. ; Prakash, Y.s. / Sex steroid signaling : Implications for lung diseases. In: Pharmacology and Therapeutics. 2015 ; Vol. 150. pp. 94-108.
@article{b5a8026e3c2746ef8a0ef99a288e747f,
title = "Sex steroid signaling: Implications for lung diseases",
abstract = "There is increasing recognition that sex hormones (estrogen, progesterone, and testosterone) have biological and pathophysiological actions in peripheral, non-reproductive organs, including the lung. Clinically, sex differences in the incidence, morbidity and mortality of lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, lung cancer and pulmonary hypertension have been noted, although intrinsic sex differences vs. the roles of sex steroids are still not well-understood. Accordingly, it becomes important to ask the following questions: 1) Which sex steroids are involved? 2) How do they affect different components of the lung under normal circumstances? 3) How does sex steroid signaling change in or contribute to lung disease, and in this regard, are sex steroids detrimental or beneficial? As our understanding of sex steroid signaling in the lung improves, it is important to consider whether such information can be used to develop new therapeutic strategies to target lung diseases, perhaps in both sexes or in a sex-specific manner. In this review, we focus on the basics of sex steroid signaling, and the current state of knowledge regarding how they influence structure and function of specific lung components across the life span and in the context of some important lung diseases. We then summarize the potential for sex steroids as useful biomarkers and therapeutic targets in these lung diseases as a basis for future translational research in the area of gender and individualized medicine.",
keywords = "Airway, Alveoli, Asthma, COPD, Estrogen, Hormone, Progesterone, Pulmonary fibrosis, Testosterone",
author = "Venkatachalem Sathish and Martin, {Yvette N.} and Y.s. Prakash",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.pharmthera.2015.01.007",
language = "English (US)",
volume = "150",
pages = "94--108",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Sex steroid signaling

T2 - Implications for lung diseases

AU - Sathish, Venkatachalem

AU - Martin, Yvette N.

AU - Prakash, Y.s.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - There is increasing recognition that sex hormones (estrogen, progesterone, and testosterone) have biological and pathophysiological actions in peripheral, non-reproductive organs, including the lung. Clinically, sex differences in the incidence, morbidity and mortality of lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, lung cancer and pulmonary hypertension have been noted, although intrinsic sex differences vs. the roles of sex steroids are still not well-understood. Accordingly, it becomes important to ask the following questions: 1) Which sex steroids are involved? 2) How do they affect different components of the lung under normal circumstances? 3) How does sex steroid signaling change in or contribute to lung disease, and in this regard, are sex steroids detrimental or beneficial? As our understanding of sex steroid signaling in the lung improves, it is important to consider whether such information can be used to develop new therapeutic strategies to target lung diseases, perhaps in both sexes or in a sex-specific manner. In this review, we focus on the basics of sex steroid signaling, and the current state of knowledge regarding how they influence structure and function of specific lung components across the life span and in the context of some important lung diseases. We then summarize the potential for sex steroids as useful biomarkers and therapeutic targets in these lung diseases as a basis for future translational research in the area of gender and individualized medicine.

AB - There is increasing recognition that sex hormones (estrogen, progesterone, and testosterone) have biological and pathophysiological actions in peripheral, non-reproductive organs, including the lung. Clinically, sex differences in the incidence, morbidity and mortality of lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, lung cancer and pulmonary hypertension have been noted, although intrinsic sex differences vs. the roles of sex steroids are still not well-understood. Accordingly, it becomes important to ask the following questions: 1) Which sex steroids are involved? 2) How do they affect different components of the lung under normal circumstances? 3) How does sex steroid signaling change in or contribute to lung disease, and in this regard, are sex steroids detrimental or beneficial? As our understanding of sex steroid signaling in the lung improves, it is important to consider whether such information can be used to develop new therapeutic strategies to target lung diseases, perhaps in both sexes or in a sex-specific manner. In this review, we focus on the basics of sex steroid signaling, and the current state of knowledge regarding how they influence structure and function of specific lung components across the life span and in the context of some important lung diseases. We then summarize the potential for sex steroids as useful biomarkers and therapeutic targets in these lung diseases as a basis for future translational research in the area of gender and individualized medicine.

KW - Airway

KW - Alveoli

KW - Asthma

KW - COPD

KW - Estrogen

KW - Hormone

KW - Progesterone

KW - Pulmonary fibrosis

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=84939998477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939998477&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2015.01.007

DO - 10.1016/j.pharmthera.2015.01.007

M3 - Article

C2 - 25595323

AN - SCOPUS:84939998477

VL - 150

SP - 94

EP - 108

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

ER -